Will recombinant Factor VIIa work in thrombocytopenia?
  Recombinant Factor VIIa is also effective in establishing hemostasis in patients with defects of platelet production, destruction, and function. A platelet surface mechanism of action of Factor VIIa also explains the efficacy of recombinant Factor VIIa in these settings. As recombinant Factor VIIa increases platelet thrombin generation, it should also be effective in patients with acquired defects of hemostasis and in surgical and trauma patients. The localized action of Factor VIIa at the surface of activated platelets prevents uncontrolled thrombin generation and fibrin deposition. Consequently, Recombinant Factor VIIa has an excellent safety profile. To date, the only cases of disseminated intravascular coagulation or thrombosis reported following Recombinant Factor VIIa therapy have occurred in patients with underlying pathological conditions in which tissue factor expression is increased. Recombinant Factor VIIa therefore has the potential for use as a general hemostatic agent.
 
 
     
back to questions
Home
end of questions
Prescribing Info - Questions - Drug Info - Links - PDA Software - Article Summaries - Slideshows - Review Articles - What's New
 
© Copyright 1999-2017 DocMD.com. All Rights Reserved.